# Songfu Jiang

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/songfu-jiang/

## Facts

| Field | Value |
| --- | --- |
| Citations | 1,269 |
| Field | Multiple Myeloma Research and Treatments |
| h-index | 21 |
| i10-index | 41 |
| Last Known Institution | Wenzhou Medical University |
| OpenAlex ID | https://openalex.org/A5046001715 |
| Works | 97 |

## Researcher papers

- [PD-L1 Is Expressed and Promotes the Expansion of Regulatory T Cells in Acute Myeloid Leukemia](https://scholariq.org/papers/pd-l1-is-expressed-and-promotes-the-expansion-of-regulatory-t-cells-in-acute/)
- [Acute Myeloid Leukemia Cells Express ICOS Ligand to Promote the Expansion of Regulatory T Cells](https://scholariq.org/papers/acute-myeloid-leukemia-cells-express-icos-ligand-to-promote-the-expansion-of/)
- [Matrine induces Akt/mTOR signalling inhibition‐mediated autophagy and apoptosis in acute myeloid leukaemia cells](https://scholariq.org/papers/matrine-induces-akt-mtor-signalling-inhibition-mediated-autophagy-and-apoptosis/)
- [Low Dose of Human scFv-Derived BCMA-Targeted CAR-T Cells Achieved Fast Response and High Complete Remission in Patients with Relapsed/Refractory Multiple Myeloma](https://scholariq.org/papers/low-dose-of-human-scfv-derived-bcma-targeted-car-t-cells-achieved-fast-response/)
- [Prognostic Significance of Pretreatment Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio in Patients with Diffuse Large B-Cell Lymphoma](https://scholariq.org/papers/prognostic-significance-of-pretreatment-neutrophil-lymphocyte-ratio-and-platelet/)
- [Phase 1 Trial of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells in Relapsed/Refractory Multiple Myeloma](https://scholariq.org/papers/phase-1-trial-of-the-safety-and-efficacy-of-fully-human-anti-bcma-car-t-cells-in/)
- [Musashi-2 Silencing Exerts Potent Activity against Acute Myeloid Leukemia and Enhances Chemosensitivity to Daunorubicin](https://scholariq.org/papers/musashi-2-silencing-exerts-potent-activity-against-acute-myeloid-leukemia-and/)
- [Two-Year Follow-up of Investigator-Initiated Phase 1 Trials of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells (CT053) in Relapsed/Refractory Multiple Myeloma](https://scholariq.org/papers/two-year-follow-up-of-investigator-initiated-phase-1-trials-of-the-safety-and/)
- [A Review of the Current Practice of Diagnosis and Treatment of Idiopathic Membranous Nephropathy in China](https://scholariq.org/papers/a-review-of-the-current-practice-of-diagnosis-and-treatment-of-idiopathic/)
- [Durable Remission Achieved from Bcma-Directed CAR-T Therapy Against Relapsed or Refractory Multiple Myeloma](https://scholariq.org/papers/durable-remission-achieved-from-bcma-directed-car-t-therapy-against-relapsed-or/)

## Researcher topics

- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Acute Myeloid Leukemia Research](https://scholariq.org/topics/acute-myeloid-leukemia-research/)
- [Immune Cell Function and Interaction](https://scholariq.org/topics/immune-cell-function-and-interaction/)

## Researcher university

- [Wenzhou Medical University](https://scholariq.org/institutions/wenzhou-medical-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.